TITLE:
Clinical Trial of Medicinal Synthetic Aluminum-Magnesium Silicate (Antivirt®) on Viral Loads and CD4-Lymphocytes Counts of HIV/AIDS Patients
AUTHORS:
Maduike C. O. Ezeibe, Dahiru Aleeyu, Ijeoma J. Ogbonna, Ekenma Kalu
KEYWORDS:
Antivirt®, Nanoparticles, Destroying Infected Cells, Unmasking “Hidden Infections”, Mopping-Out HIV
JOURNAL NAME:
World Journal of AIDS,
Vol.6 No.2,
April
22,
2016
ABSTRACT: For clinical trial of
Medicinal synthetic Aluminum-magnesium silicate (MSAMS, Antivirt®), on viral
loads and CD4-lymphocytes counts of HIV/AIDS patients, 10 volunteers were
treated. Their blood samples were tested for viral loads and for
CD4-lymphocytes counts, before the treatment and every 4 weeks during the
medication. The regimen was: MSAMS (50 mg/kg), MSAMS-stabilized Ampicillin
trihydrate (7.5 mg/kg) and immunace extra protection® (1 tablet/day), for 4
weeks. Then, it was reduced to 50 mg/kg (MSAMS) and the immune stimulant. When
their viral loads become undetectable, they would be treated for additional 4
weeks. Initially, the Antivirt®-regimen appeared to worsen both HIV
infection-load and immune deficiency but later relieved them. Patients’ mean-viral
load increased (P = 0.020), from 1820.30 ± 868.75 to 2855.90 ± 960.98, after 4
weeks before reducing (P = 0.030) to 1565.20 ± 743.17, after 8 weeks.
Similarly, their mean-CD4-lymphocytes count reduced (P = 0.008) from 496.80 ±
194.39 to 263.90 ± 149.26, after 4 weeks before improving (P = 0.001) to 507.90
± 133.19, after 8 weeks.